Page 48 - Assessing right ventricular function and the pulmonary circulation in pulmonary hypertension Onno Anthonius Spruijt

3
Characteristics
Age (years) Women
White
Etiology of PAH
Idiopathic or familial
Drugs and toxin (history of use) Body mass index (kg/m2)
Right heart catheterization
HR (BPM)
SBP (mmHg) RAP (mmHg) mPAP (mmHg) PAWP (mmHg) CI (L/min/m2) PVRI (WUxm2)
6MWD (m)
DLCO (%)
Comorbid conditions
CKD (eGFR <60ml/min/1.73m2) Hyponatremia (<136 mEq/l) Diabetes mellitus
Systemic hypertension
Medication Diuretics
Prostanoid therapy PDE5I
ERA
Warfarin
n=95
43±11 75 (79%) 84 (88%)
44 (46%) 51 (55%) 30±6
82±14 120±17 10±6 54±14 10±4 2.0±0.6 25±12 432±117 75±23
22 (23%) 9 (9.5%) 3 (3%) 4 (4%)
48 (51%) 43 (45%) 31 (33%) 39 (41%) 59 (63%)
Table 1: Values are mean ± SD or n (%). CI = cardiac index; CKD = chronic kidney disease; DLCO = diffusion of carbon monoxide; eGFR = estimated glomerular filtration rate; HR = heart rate, mPAP = mean pulmonary arterial pressure; PAH = pulmonary arterial hypertension; PAWP = pulmonary capillary wedge pressure; PVRI = pulmonary vascular resistance index; RAP = right atrial pressure; SBP = systolic blood pressure.
Table 1 summarizes the characteristics of the study population. The average follow-up time for our study was 5.0±2.4 years. The mean pulmonary arterial pressure was 54±14mmHg, and the